Overview of fluoroquinolone safety

The American Journal of Medicine

Volumn 91, Issue 6 SUPPL. 1, 1991, Pages

  Wolfson, John S ^a   Hooper, David C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTACID AGENT; CAFFEINE; CIMETIDINE; CIPROFLOXACIN; CYCLOSPORIN; ENOXACIN; FENBUFEN; FLEROXACIN; LOMEFLOXACIN; NONSTEROID ANTIINFLAMMATORY AGENT; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TEMAFLOXACIN; THEOPHYLLINE; WARFARIN;

ADVERSE DRUG REACTION; BACTERIAL INFECTION; CONFERENCE PAPER; HUMAN; PRIORITY JOURNAL;

ANTI-INFECTIVE AGENTS, QUINOLONE; DRUG INTERACTIONS; HUMAN;

EID: 0026341296     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/0002-9343(91)90330-Z     Document Type: Article

References (188)

1. The tolerability profile of prophylactic norfloxacin in neutropenic patients
2. The safety profile of ofloxacin
3. Safety of intravenous ciprofloxacin in healthy volunteers after multiple dosing
4. Fluoroquinolone antimicrobial agents
5. Fluoroquinolone antimicrobial agents
6. Phase IV study and post-marketing surveillance of ofloxacin in Japan
7. Second international symposium on new quinolones
8. Ciprofloxacin major advances in intravenous and oral quinolone therapy
9. Pefloxacin in clinical practice
10. Update on new quinolones
11. Comparison of ciprofloxacin and co-trimoxazole in the treatment of uncomplicated urinary tract infection in women
12. Comparative trial of single-dose ciprofloxacin and ampicillin plus probenecid for treatment of gonococcal urethritis in men
13. Ciprofloxacin or trimethoprim-sulfamethaxazole as initial therapy for travelers' diarrhea
14. Treatment of nongonococcal urethritis with ciprofloxacin
15. Treatment of chancroid with ciprofloxacin: a prospective, randomized clinical trial
16. Clinical efficacy of ciprofloxacin compared with placebo in bacterial diarrhea
17. Comparative double-blind study of oral ciprofloxacin and intravenous cefotaxime in skin and skin structure infections
18. Effect of ciprofloxacin on carrier rate of Neisseria meningitidis in army recruits in Finland
19. Use of ciprofloxacin in the treatment of serious skin and skin structure infections
20. Controlled, comparative study of ciprofloxacin versus ampicillin in treatment of bacterial respiratory tract infections
21. Randomized, double-blind comparison of ciprofloxacin and trimethoprim-sulfamethoxazole for complicated urinary tract infections
22. Comparison of ciprofloxacin with ampicillin in acute infectious exacerbations of chronic bronchitis
23. Oral ciprofloxacin vs parenteral cefotaxime in the treatment of difficult skin and skin structure infections
24. Therapy for shigellosis. II. Randomized, double-blind comparison of ciprofloxacin and ampicillin
25. A prospective, double-blind randomized study comparing the efficacy and safety of low-dose ciprofloxacin with ampicillin in the treatment of bronchitis
26. Ciprofloxacin compared with doxycycline for nongonococcal urethritis
27. Pharmacokinetics and tolerance of enoxacin in healthy volunteers administered at a dosage of 400 mg twice daily for 14 days
28. Coordinated multicenter study of norfloxacin versus trimethoprim-sulfamethoxazole treatment of symptomatic urinary tract infections
29. Norfloxacin versus placebo for prophylaxis against travelers' diarrhea
30. Double-blind, randomized comparison of 24 weeks of norfloxacin and 12 weeks of norfloxacin followed by 12 weeks of placebo in therapy of complicated urinary tract infection
31. Use of norfloxacin to treat chronic typhoid carriers
32. Norfloxacin versus co-trimoxazole in the treatment of acute bacterial diarrhoea: a placebo controlled study
33. Norfloxacin versus co-trimoxazole for the treatment of upper urinary tract infections: a double blind study
34. Treatment of urinary tract infections in Hong Kong: a comparative trial of norfloxacin and co-trimoxazole
35. Prospective, randomized, placebo-controlled trial of norfloxacin for the prophylaxis of recurrent urinary tract infection in women
36. Randomised double-blind study of norfloxacin and cefadroxil in the treatment of acute pyelonephritis
37. The efficacy and safety of ciprofloxacin and ofloxacin in chronic Pseudomonas aeruginosa infection in cystic fibrosis
38. A clinical comparative trial of ofloxacin and pivampicillin in acute exacerbations of chronic bronchitis
39. Ofloxacin compared with ciprofloxacin in the treatment of complicated lower urinary tract infections
40. Treatment of non-gonococcal urethritis: comparison of ofloxacin and erythromycin
41. Single dose pefloxacin compared with multiple dose co-trimoxazole in cystitis
42. Single-dose pefloxacin versus five-days treatment with norfloxacin in uncomplicated cystitis in women
43. Assessment of adverse events during drug development: experience with temafloxacin
44. Clostridium difficile colitis associated with ofloxacin therapy
45. Clostridium difficile-associated diarrhea after norfloxacin
46. Ciprofloxacin as a cause of Clostridium difficile-associated diarrhoea in an HIV antibody-positive patient
47. Pseudomembranous colitis associated with ciprofloxacin
48. Ciprofloxacin and Clostridium difficile infection
49. Ciprofloxacin and pseudomembranous colitis
50. Ciprofloxacin and pseudomembranous colitis
51. Ciprofloxacin and pseudomembranous colitis
52. Oral fluoroquinolone therapy in Clostridium difficile colitis
53. A new approach to the treatment of pseudomembranous colitis?
54. Brief report safety of ciprofloxacin based on Phase IV (“Anwendungsbeobachtung”) in the Federal Republic of Germany
55. Safety of oral ciprofloxacin an update based on clinical trials
56. Central nervous system toxicity of quinolones: human and animal findings
57. Ofloxacin-associated psychosis
58. Neurologic toxicity related to pefloxacin
59. Ciprofloxacin and delerium
60. Acute psychoses associated with the use of ciprofloxacin and trimethoprim-sulfamethoxazole
61. Norfloxacin and seizures
62. Grand mal epileptic seizures during ciprofloxacin therapy
63. Drug interactions with quinolones
64. Specific toxicologic aspects of the quinolones
65. Seizure discharges induced by the combination of a new quinolonecarboxylic acid antimicrobial drugs and non-steroidal anti-inflammatory drugs
66. Inhibitory effects of quinolone antibacterial agents on gamma-aminobutyric acid binding to receptor sites in rat brain membranes
67. Toxicity of the quinolones
68. Adverse reactions in a dose-ranging study with a new long-acting fluoroquinolone, fleroxacin
69. Ciprofloxacin-induced photosensitivity: in vitro and in vivo studies
70. Phototoxic potential of quinolone antibacterial agents in Balb/c mice
71. Ciprofloxacin-induced vasculitis
72. Fatal vasculitis associated with ofloxacin
73. Serum sickness-like illness associated with ciprofloxacin
74. Anaphylactoid reactions reported after treatment with ciprofloxacin
75. Fatal anaphylaxis associated with AIDS related complex
76. Safety of intravenous ciprofloxacin a review
77. Tolerance of ciprofloxacin at injection site, systemic safety and effect on electroencephalogram
78. Treatment of genitourinary tract infections with fluoroquinolones: clinical efficacy in genital infections and adverse effects
79. Double-blind comparison of 3-day versus 7-day treatment with norfloxacin in symptomatic urinary tract infections
80. Long-term use of quinolones and their safety
81. Ciprofloxacin-induced hematuria
82. Summary of a workshop on ciprofloxacin use in patients with cystic fibrosis
83. Ciprofloxacin and allergic interstitial nephritis
84. Allergic nephropathy associated with ciprofloxacin
85. Ciprofloxacin-induced allergic interstitial nephritis
86. Case report of renal failure during norfloxacin therapy
87. Acute renal failure secondary to oral ciprofloxacin therapy: a presentation of three cases and a review of the literature
88. Acute renal failure due to ciprofloxacin
89. Acute renal failure after an overdose of ciprofloxacin
90. Arthropathy induced by antibacterial fused N-alkyl-4-pyridone-3-carboxylic acids
91. Toxicokinetic study of norfloxacin-induced arthropathy in juvenile animals
92. Comparison of organ-specific toxicity of temafloxacin in animals and man
93. Ofloxacin in juvenile non-human primates and rats
94. Nalidixic acid arthralgia
95. Norfloxacin-induced rheumatic disease
96. Ciprofloxacin and tenosynovitis
97. Risk/benefit analysis of quinolone use in children: the effect on diarthodial joints
98. Arthropathy in a patient with cystic fibrosis taking ciprofloxacin
99. Nalidixic acid in children: retrospective matched controlled study for cartilage toxicity
100. Use of quinolones in pediatric patients
101. Use of quinolones in childhood
102. Parenteral fluoroquinolones for the treatment of children with life-threatening infections not responding to other antibiotics
103. Potential role of fluoroquinolones in pediatric infections
104. Antibiotics in the management of shigellosis in children: what role for the quinolones?
105. Parenteral fluoroquinolones in children with life-threatening infections
106. Quinolones in children with invasive salmonellosis
107. Joint tolerance of pefloxacin and ofloxacin in children and adolescents with cystic fibrosis
108. Knorpelschadigende Wirkung der Chinolone
109. Norfloxacin disposition after sequentially increasing oral doses
110. Crystalluria and ciprofloxacin, influence of urinary pH and hydration
111. Mechanism of inhibition of DNA gyrase by analogues of nalidixic acid: the target of the drugs is DNA
112. Mechanism of quinolone inhibition of DNA gyrase: appearance of unique norfloxacin binding sites in enzyme-DNA complexes
113. Immunological aspects of new quinolones
114. Norfloxacin: review of safety studies
115. Ciprofloxacin: a review of its antibacterial activity, pharmacokinetic properties and therapeutic use
116. Reproductive toxicity of ofloxacin
117. Quinolone antimicrobial agents and ophthalmologic infections
118. Drug interactions of ciprofloxacin with other non-antibiotic agents
119. Overview of drug interactions with the quinolones
120. Inhibition of drug metabolism by quinolone antibiotics
121. Drug interactions with quinolones
122. Adverse effects of quinolone antimicrobial agents
123. Drug-drug interactions with ciprofloxacin and other fluoroquinolones
124. Adverse reactions to fluoroquinolones
125. Side-effects of quinolones: comparisons between quinclones and other antibiotics
126. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin effect of food and antacid intake
127. Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin
128. Inhibition of enoxacin absorption by antacid or ranitidine
129. Effects of cimetidine on the pharmacokinetics of pefloxacin in healthy volunteers
130. Inhibition of norfloxacin absorption by antacids
131. Effects of magnesium-aluminum hydroxide and calcium carbonate antacids on bioavailability of ofloxacin
132. Effect of staggered dose of calcium on the bioavailability of ciprofloxacin
133. The effect of sucralfate pretreatment on the pharmacokinetics of ciprofloxacin
134. Effect of ferrous sulfate and multivitamins with zinc on absorption of ciprofloxacin in normal volunteers
135. Clinical and chemical interactions between iron preparations and ciprofloxacin
136. The influence of quinolone derivatives on theophylline clearance
137. Interaction between the fluoroquinolones and the bronchodilator theophylline
138. Inhibition of the oxidative metabolism of theophylline in isolated rat hepatocytes by the quinolone antibiotic enoxacin and its metabolite oxoenoxacin but not by norfloxacin
139. The possible mechanism of interaction between xanthines and quinolones
140. In vitro effect of fluoroquinolones on theophylline metabolism in human liver microsomes
141. New synthetic quinolone antibacterial agents and serum concentration of theophylline
142. Effect of norfloxacin on theophylline pharmacokinetics at steady state
143. Evaluation of the effect of norfloxacin on pharmacokinetics of theophylline
144. Effects of enoxacin, ofloxacin and norfloxacin on theophylline deposition in humans
145. Effect of norfloxacin on theophylline metabolism
146. Pharmacokinetics of ofloxacin and theophylline alone and in combination
147. Inhibition of theophylline clearance by coadministered ofloxacin without alteration of theophylline effects
148. The newest quinolone antibacterial agents and theophylline
149. Effect of lomefloxacin on theophylline pharmacokinetics
150. Influence of lomefloxacin on the pharmacokinetics of theophylline
151. Comparative effects of ciprofloxacin and lomefloxacin on the oxidate metabolism of theophylline
152. The effect of multiple-dose oral lomefloxacin on theophylline metabolism in man
153. Safety of fleroxacin coadministered with theophylline to young and elderly volunteers
154. Comparative studies on interaction between theophylline and quinolones
155. Effect of a new quinolone, sparfloxacin, on the pharmacokinetics of theophylline in asthmatic patients
156. Theophylline dosage adjustment during enoxacin administration
157. Gyrase-hemmer konnendie coffein-elimination verzogern
158. Pharmacokinetics and clinical effects of caffeine alone and in combination with oral enoxacin
159. Ciprofloxacin-caffeine a drug interaction established using in vivo and in vitro investigations
160. Interaction between oral ciprofloxacin and caffeine in normal volunteers
161. Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition
162. Effect of quinolones on caffeine disposition
163. Lack of interaction between lomefloxacin and caffeine in normal volunteers
164. Caffeine as a potential risk factor for theophylline neurotoxicity
165. Assessment of quinolone neurotoxicity in rodents
166. Quinolones, theophylline, and diclofenac interaction with the gamma-aminobutyric acid receptor
167. Effect of the antiinflammatory agent fenbufen on the quinolone-induced inhibition of gamma-aminobutyric acid binding to rat brain membranes in vitro
168. Interactions of quinolones with opioids and fenbufen, a nonsteroidal antiinflammatory drug: involvement of dopaminergic neurotransmission
169. Hippocampal activity in the presence of quinolones and fenbufen in vitro
170. The effects of quinolones and NSAIDs upon GABA-evoked currents recorded from rat dorsal root ganglion neurones
171. Enoxacinwarfarin interaction: pharmacokinetic and stereochemical aspects
172. Ofloxacin and warfarin
173. Norfloxacin and warfarin
174. Ciprofloxacin and warfarin
175. Adverse reaction reporting of interaction between warfarin and fluoroquinolones
176. Ciprofloxacin and warfarin interaction
177. Synergistic nephrotoxicity due to ciprofloxacin and cyclosporine
178. Possible interaction of ciprofloxacin with cyclosporin A
179. Norfloxacin-cyclosporine interaction
180. Cyclosporine (cyclosporin A) pharmacokinetics in renal transplant patients receiving ciprofloxacin
181. Investigation of potential interaction of ciprofloxacin with cyclosporine in bone marrow transplant recipients
182. Patients receiving quinolones and cyclosporine after heart transplantation
183. Effect of ciprofloxacin on cyclosporine pharmacokinetics
184. Norfloxacin and cyclosporine: a safe combination